Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

Sustainable Development

Sustainable Development

As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The ethical and responsible use of sick call.

Journal of the American Academy of Dermatology·2024

Same author

Ethics of dynamic and differential pricing for cosmetic procedures.

Clinics in dermatology·2024

Same author

Patient satisfaction with teledermatology: A systematic review and meta-analysis.

Journal of the American Academy of Dermatology·2024

Same author

Ethics of attending paid "dinner lecture consultations".

Journal of the American Academy of Dermatology·2024

Same author

Dermatologic toxicities of antibody-drug conjugates.

Journal of the American Academy of Dermatology·2024

Same author

To Google, or not to Google, that is the question: Ethics of internet searches when caring for incarcerated individuals.

Journal of the American Academy of Dermatology·2024

Search research articles

Related Experiment Video

Updated: Feb 13, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Pediatric Melanoma and Drug Development.

Klaus Rose¹, Jane M Grant-Kels²

¹klausrose Consulting, Pediatric Drug Development & More, 4125 Riehen, Switzerland. klaus.rose@klausrose.net.

Children (Basel, Switzerland)

|March 21, 2018

Summary

Regulatory-mandated pediatric melanoma studies are medically unnecessary. Effective combination treatments should be used for all melanoma patients, with special attention to infants and dose-finding studies for children, while adolescents can be treated similarly to adults.

Keywords:

EU pediatric regulation Pediatric Investigation Plan (PIP)developmental pharmacology pediatric clinical pharmacology pediatric clinical studies pediatric drug development pediatric laws pediatric pharmaceutical legislation

More Related Videos

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

Related Experiment Videos

Last Updated: Feb 13, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

Area of Science:

Oncology
Pediatric Medicine
Clinical Pharmacology

Background:

Pediatric melanoma is rare but raises questions about treatment protocols.
Regulatory bodies often demand separate clinical studies for pediatric populations.
Current regulations define pediatric patients by age, not physiological maturity.

Purpose of the Study:

To evaluate the medical necessity and beneficence of industry-sponsored pediatric melanoma studies.
To analyze the rationale behind regulatory demands for pediatric drug studies.
To advocate for evidence-based treatment for all melanoma patients.

Main Methods:

Identification of international pediatric melanoma clinical trials via clinicaltrials.gov.
Retrieval and analysis of related regulatory documents.
Assessment of study rationale based on physiology and pediatric clinical pharmacology.

Main Results:

Identified numerous pediatric melanoma studies driven by regulatory requirements (e.g., EU Pediatric Investigation Plans).
Found that regulatory age-based definitions lack medical sense, as physiological maturity varies.
Observed that adolescent drug metabolism and response are similar to adults, making separate studies often medically superfluous.

Conclusions:

Regulatory-mandated pediatric melanoma studies are medically unnecessary and often lack beneficence.
Melanoma patients of all ages, including adolescents, should receive effective combination treatments.
Ethics committees should suspend and reject questionable pediatric melanoma studies, focusing instead on age-appropriate research like dose-finding and pharmacokinetic studies for younger children.